The endocannabinoid system is an important player in energy metabolism by regulating appetite, lipolysis and energy expenditure. Chronic blockade of the cannabinoid 1 receptor (CB1R) leads to long-term maintained weight loss and reduction of dyslipidemia in experimental and human obesity. The molecular mechanism by which CB1R blockade reverses dyslipidemia in obesity has not been clarified yet. In this study, we showed that CB1R blockade with the systemic CB1R blocker rimonabant enhanced whole-body energy expenditure and activated brown adipose tissue (BAT) indicated by by increased expression of genes involved in BAT thermogenesis and decreased lipid droplet size in BAT. This was accompanied by selectively increased triglyceride (TG) uptake by BAT and lower plasma TG levels.
Introduction
The endocannabinoid system regulates a broad range of physiological functions (1) and consists of G-protein coupled cannabinoid receptors, its endogenous lipid ligands (endocannabinoids) and the enzymes involved in the biosynthesis and degradation of endocannabinoids (2, 3) . The cannabinoid type 1 receptor (CB1R) is expressed at high levels in the brain but also at functionally relevant concentrations in various peripheral tissues (1) . In contrast, the cannabinoid type 2 receptor is mainly expressed on immune cells (4) . CB1R knockout mice display reduced adiposity and are resistant to diet-induced obesity (5) . Moreover, overweight and obese humans exhibit an overactive endocannabinoid system (6, 7) , suggesting a role of the endocannabinoid system in energy metabolism.
Chronic systemic blockade of the CB1R with the inverse agonist rimonabant leads to long-term maintained weight loss and reduction of dyslipidemia in obese rodents (8, 9) and humans (10) (11) (12) (13) . Rimonabant was considered one of the most promising therapeutic drugs to treat obesity, until the appearance of central psychiatric side effects resulted in its removal from the market in 2008. Nevertheless, several lines of evidence indicate that the effect of CB1R blockade is not restricted to a central mode of action, especially since the CB1R has been shown to be present in peripheral tissues including the liver (14) , skeletal muscle (15) and adipocytes (16) .
More specifically, Tam et al. (17) recently showed that the strictly peripheral CB1R antagonist AM6545 induced weight loss and diminished hepatic steatosis in a mouse model. Thus, it seems plausible that psychiatric side effects can be avoided by strict peripheral blockade of the CB1R, while retaining the beneficial anti-obesity and lipid-lowering effects.
Despite clear evidence that pharmacological CB1R antagonism improves dyslipidemia, the exact mechanisms and the peripheral tissues involved have not yet been elucidated. Recently, brown adipose tissue (BAT) emerged as an important player in triglyceride (TG) clearance (18) . In contrast to white adipose tissue (WAT), which stores excess TG as fat, BAT dissipates energy into heat, a process mediated by the mitochondrial uncoupling protein-1 (UCP-1) (19) . The best known trigger for activation of BAT is cold, which increases sympathetic outflow from the hypothalamic temperature centre towards BAT, leading to release of noradrenalin and increased thermogenesis (19) . Metabolically active BAT stores exist in adult humans (20) (21) (22) , and BAT volume and activity are lower in obese subjects (21) . In addition, BAT volume and activity are lower in South Asians, a population prone to develop type 2 diabetes mellitus and cardiovascular disease (23) . Together, these findings have increased interest in the therapeutic potential of BAT to combat obesity and related disorders, such as dyslipidemia.
In this study, we aimed at elucidating the molecular mechanism by which CB1R blockade attenuates dyslipidemia in diet-induced obesity by using a mouse model for human-like lipoprotein metabolism.
MATERIALS & METHODS

Animals and diet
Homozygous human cholesteryl ester transfer protein (CETP) transgenic mice were crossbred with hemizygous APOE*3-Leiden (E3L) mice at our Institutional Animal
Facility to obtain E3L.CETP mice, as previously described (24) . We chose to perform our studies in this specific mouse model, since these mice are a well-established model for human-like lipoprotein metabolism and respond to lipid-lowering pharmacological interventions (24) (25) (26) . In all the studies described below, 10 weekold E3L.CETP male mice were housed under standard conditions in conventional cages in a 12:12 h light: dark cycle with ad libitum access to food and water, and were fed a high-fat diet (HFD; Research diets, New Brunswick, USA, 60% lard fat) for 12 weeks to induce obesity. From the 7 th week onwards, the drinking water was 
Pharmacological intervention
After 12 weeks of HFD, diet-induced obese (DIO) mice were randomised according to their body weight and plasma total cholesterol (TC) and triglyceride (TG) levels into four groups. Subsequently, mice were housed at either 21°C (subthermoneutral) or 28°C (thermoneutral), and received 60% HFD with or without 10 mg/kg body weight/ day (0.00885%, w/w) rimonabant (Axon Medchem, Groningen, the Netherlands) or AM6545 (Sigma-Aldrich, St. Louis, USA) for 4 weeks.
Body weight and food intake
In all experiments, mice were housed individually during the 4 week treatment period. Food intake was recorded daily by weighing the food that was left in the cage or was recorded automatically in metabolic cages (see below). Body weight was measured twice a week.
Indirect calorimetry and physical activity
Indirect calorimetry was performed in fully automatic metabolic cages (LabMaster System, TSE Systems, Bad Homburg, Germany) during the fourth week of treatment.
After 20 h acclimatization, oxygen uptake (V˙ O 2 ), carbon dioxide production (V˙ CO 2 ) and caloric intake were measured for 5 consecutive days. Carbohydrate (CHO) and fat oxidation rates were calculated from V˙ O 2 and V˙ CO 2 as described previously (27) .
Total energy expenditure (EE) was calculated from V˙ O 2 and V˙ CO 2 using the Weir equation (28) . Physical activity was measured using infrared sensor frames.
Dual-energy X-ray absorptiometry (DEXA) scan
After 4 weeks treatment, body composition was measured by DEXA using the Norland pDEXA Sabre X-ray Bone Densitometer. Mice were anaesthetized intraperitoneally with a combination of 6.25 mg⁄kg acepromazine (Alfasan), 6.25 mg⁄kg midazolam (Roche) and 0.31 mg⁄kg fentanyl (Janssen-Cilag). The total body of the mice was
scanned, yet the heads were excluded from the analyses.
Plasma parameters
Blood was collected from the tail vein of 4-6 hour fasted mice into chilled capillaries that were coated with paraoxon (Sigma, St. Louis, MO) to prevent ongoing lipolysis (29) .
Capillaries were placed on ice and centrifuged, and plasma was assayed for TG, TC, and phospholipids (PL) using commercially available enzymatic kits from Roche Diagnostics (Mannheim, Germany for TG and TC) and Instruchemie (Delfzijl, the Netherlands for PL). Free fatty acids (FFA) were measured using NEFA C kit from Wako Diagnostics (Instruchemie, Delfzijl, The Netherlands).
Lipoprotein profiles
To determine lipid distribution over plasma lipoproteins, pooled plasma was used for fast performance liquid chromatography (FPLC). Plasma was injected onto a Superose 6 column (ÄKTA System, Amersham Pharmacia Biotech, Piscataway, NJ) and eluted at a constant flow rate of 50 µL/min with PBS pH 7.4. TG and TC were measured as described above in collected fractions of 50 µL.
In vivo clearance of labeled VLDL-like emulsion particles 
RNA isolation and qRT-PCR analysis
Total RNA was isolated with the Nucleospin® RNA II Kit (Macherey-Nagel) according to the manufacturer's instructions. 1 μg of total RNA was reverse-transcribed with iScript cDNA synthesis kit (Bio-Rad), and the obtained cDNA was purified with Nucleospin Extract II kit (Macherey-Nagel). Real-time PCR was carried out on the IQ5
PCR machine (Bio-Rad) using the Sensimix SYBR Green RT-PCR mix (Quantace). Melt curve analysis was included to assure a single PCR product was formed. Expression levels were normalized using glyceraldehyde-3-phosphate dehydrogenase (Gapdh), β2-microglobulin and 36b4 as housekeeping genes. Primer sequences are listed in Table 1 .
Histology
Interscapular BAT, liver and sWAT were removed and fixed directly in 4% 
In vitro experiments with brown adipocytes
The murine brown preadipocyte cell line T37i (34) was cultured in HAM'S-F12 medium (Gibco-Invitrogen) supplemented with 10% fetal calf serum, 2 mM HEPES, 100 U/mL penicillin and 100 μg/mL streptomycin (Gibco-Invitrogen). For experiments, T37i cells were seeded in 6-wells plates and grown towards confluence. Two days after reaching confluence, cells were differentiated using normal culture medium supplemented with 2 nM triiodothyronine (T3) (Sigma) and 112 ng/mL bovine insulin (Sigma). The differentiation medium was replaced every 2 or 3 days. After 9 days of Subsequent experiments were performed after pre-incubation for 1 h with and in the presence of PKA inhibitor H89 (25µM). Then, 500 µL of supernatant was collected and snap-frozen in liquid nitrogen. Cells were washed twice with ice-cold PBS and cells were harvested in ice-cold lysis buffer as described below.
Oxygen consumption measurements 
Protein isolation and Western blot
T37i cells or snap-frozen tissue samples were lysed in ice-cold buffer containing 50 mM Hepes (pH 7.6), 50 mM NaF, 50 mM KCl, 5 mM NaPPi, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 5 mM β-glycerophosphate, 1 mM sodium vanadate, 1% NP40 and protease inhibitors using cocktail tablets (Roche). Homogenates were centrifuged at 13,000 rpm for 15 min at 4°C and the protein content of the supernatant was determined using the BCA Protein Assay Kit from Thermo Scientific. Proteins (20 μg) were separated by 10% SDS-PAGE followed by transfer to a polyvinylidene fluoride transfer membrane (Merck, Amsterdam, The Netherlands). Membranes were blocked for 1 h at room temperature in Tris-buffered saline tween-20 buffer with 5% non-fat dry milk followed by an overnight incubation with specific primary antibodies. Primary antibodies specific for cannabinoid type 1 receptor (CB1R), E2-F, AMPK, P-AMPK, ACC, P-ACC, P-HSL (ser563), P-HSL (ser565) and tubulin were purchased from Cell Signaling (Leiden, The Netherlands). A primary antibody specific for uncoupling protein 1 (UCP1) was purchased from Sigma-Aldrich. All antibodies were diluted 1:1000. Blots were incubated with horseradish peroxidaseconjugated secondary antibodies for 1 h at room temperature. Bands were visualized with SuperSignal West Pico Chemiluminescent Substrate (Pierce) and quantified using ImageJ (version 1.47).
Statistical analysis
All data are expressed as mean ± SEM. Statistical analysis using the unpaired two-tailed Student's test was performed with the SPSS 20.0 software package for Windows (SPSS, Chicago, United States) to determine differences between vehicleand compound-treated groups. A P-value < 0.05 was considered statistically significant.
RESULTS
Systemic CB1R blockade by rimonabant in DIO mice reduces obesity and dyslipidemia and increases energy expenditure
To investigate the effect of systemic CB1R blockade on body composition and energy balance, E3L.CETP transgenic mice were fed a HFD for 12 weeks to render them obese (mean body weight: 53.2 ± 0.9 g) and treated with rimonabant or vehicle for 4 weeks.
Rimonabant elicited a profound decrease in body mass (-25%, p<0.001; Figure 1A ) which was not due to a decrease in lean mass but rather to a massive decrease in fat mass (-32%, p<0.001; Figure 1B ). Rimonabant decreased caloric intake transiently (i.e. until day 6) (Figure 1C ), in accordance with previous observations (35, 36) , while it persistently induced weight loss throughout the treatment period (i.e. 4 weeks).
Furthermore, rimonabant markedly diminished plasma TG levels (-59%, p<0.05) and TC levels (-40%, p<0.01) ( Figure 1D ), which is in line with previous human studies (10) (11) (12) . Rimonabant tended to reduce plasma phospholipid (PL) levels (-31%, p=0.05) and had no effect on plasma free fatty acid (FFA) levels. Lipoprotein profiling showed that the marked decrease in plasma TG mostly resulted from a reduction in VLDL-TG (AUC -62%) ( Figure 1E ). The persistent reduction in body weight despite the transient decrease in food intake following rimonabant treatment suggests increased energy expenditure. Indeed, rimonabant increased substrate utilization reflected by increased fat oxidation (+18%, p<0.05; Figure 1F ), carbohydrate (CHO) oxidation (+18%, p<0.05; Figure 1G ), and consequently total energy expenditure (+17%, p<0.05; Figure 1H ), as measured via indirect calorimetry, without increasing locomotor activity ( Figure 1I) or RQ values (data not shown).
Systemic CB1R blockade by rimonabant attenuates dyslipidemia by activating brown adipose tissue
Plasma VLDL-TG levels are determined by the balance between hepatic VLDL-TG production and VLDL-TG clearance by lipoprotein lipase (LPL)-expressing peripheral organs. Therefore, to gain insight into the mechanism by which systemic CB1R
antagonism reduces plasma VLDL-TG, we first assessed the effect of rimonabant on VLDL production. DIO mice were treated with rimonabant or vehicle for 4 weeks and then sequentially injected with Trans 35 S and Triton WR1339 resulting in linear accumulation of VLDL in which newly synthesized apolipoproteins are radiolabeled.
Rimonabant did not affect the time-dependent accumulation of plasma TG following
Triton injection (Figure 2A) . Therefore, the VLDL-TG production rate, as determined from the slope of the curve, was not significantly different. In addition, the rate of VLDL-apoB production did not change ( Figure 2B ). In line with these observations, hepatic expression of lipogenic genes such as fatty acid synthase (Fasn) and stearoyl-CoA desaturase (Scd1) was unchanged ( Figure 2C ). All together, these data demonstrate that global CB1R antagonism does not diminish dyslipidemia by lowering hepatic VLDL-TG production.
To investigate whether rimonabant increases VLDL-TG clearance, we determined the kinetics of i.v. injected To further investigate the mechanism by which systemic CB1R blockade increased FA uptake by BAT, we determined the mRNA expression of genes involved protein that mediates thermogenesis (+49%, p<0.05). Furthermore, histology showed a more intense immunohistochemical staining of UCP-1 in BAT ( Figure 2G) as well as a decrease in intracellular lipid droplet size, reflected by a decrease in relative lipid area (-39%, p<0.001; Figure 2H ), both pointing to more active BAT (37) .
Thus, these data provide strong evidence that systemic CB1R antagonism diminishes dyslipidemia and increases energy expenditure, by promoting VLDL-TG uptake and subsequent combustion by BAT.
Systemic CB1R blockade by rimonabant diminishes TG storage in WAT and liver
To investigate whether the increased flux of TG towards BAT reduces (ectopic) TG accumulation, we analyzed WAT and the liver in more detail. Indeed, from the VLDL-TG clearance experiment it appeared that retention of [
3 H]TO-derived activity by the energy storing sWAT depot was diminished after rimonabant treatment (-42%, p<0.05; Figure 2E ). In line with this, the cell size of white adipocytes was decreased in this depot as evident after H&E staining (Supplemental Figure 1A) . In addition, rimonabant diminished expression of the lipogenic genes Fasn (-58%, p<0.05) and Figure 1C) , suggesting that the enhanced FA efflux from WAT may occur secondary to the enhanced BAT activation.
In liver, rimonabant markedly decreased liver weight (Supplemental Figure 2A) , which was accompanied by a reduction in liver TG content (-45%, p<0.01) (Supplemental Figure 2B ) and smaller intracellular lipid vacuoles (Supplemental Figure 2C) .
Furthermore, rimonabant caused a (likely compensatory) downregulation of hepatic expression of genes involved in lipid oxidation, such as acyl-CoA synthetase longchain family member 1 (Acsl1) and acetyl-CoA carboxylase 2 (Acc2) (Supplemental Figure 2D) , while genes involved in lipogenesis were not affected ( Figure 2C) . Thus, these data suggest that systemic CB1R blockade reduces storage of TG in WAT and liver, which may, at least in part, be a consequence of increased FA demand and flux towards BAT.
The anti-obesity and lipid-lowering effects of systemic CB1R blockade by rimonabant are not abrogated at thermoneutrality BAT is densely innervated by the sympathetic nervous system (SNS) (19) . Therefore, one of the mechanisms by which systemic CB1R blockade may lead to BAT activation could involve central CB1R blockade resulting in increased sympathetic outflow towards BAT. To investigate whether rimonabant acts centrally by increasing sympathetic nervous system (SNS) activation towards BAT, we next evaluated the effects of rimonabant in DIO mice that were housed at thermoneutral temperature (28°C). At thermoneutrality, rimonabant still markedly reduced obesity ( Figure 3A,B) without affecting lean mass. This was accompanied by a transient decrease in food intake (i.e. until day 6) (Figure 3C) . Importantly, at thermoneutrality rimonabant still lowered plasma TG (-70%, p<0.05; Figure 3D) , which was mainly due to a reduction in VLDL-TG (AUC -52%; Figure 3E ). Furthermore, rimonabant still increased whole-body fat and carbohydrate oxidation (Supplemental Figure 3A,B) , resulting in increased total energy expenditure (+21%, p<0.05; Figure 3F ), accompanied by increased markers of BAT activation both on mRNA ( Figure 3G ) and histological levels ( Figure 3H ). Thus, these data suggest that the reduction in dyslipidemia, increase in energy expenditure and activation of BAT by systemic CB1R blockade occurs at least in part independent of SNS activation of BAT.
In vitro CB1R blockade by rimonabant induces activation of brown adipocytes which is at least in part mediated by PKA signaling
To explore the possibility that direct blockade of a CB1R in BAT may be responsible for the anti-obesity and lipid-lowering effect induced by systemic CB1R blockade, we first investigated whether the CB1R is expressed on BAT. Indeed, western blots on protein from tissues derived from untreated mice showed that the CB1R is highly expressed in BAT (Figure 4A ), even when compared to the expression in hypothalamus and liver. In vitro treatment of T37i brown adipocytes with rimonabant (1 μM) enhanced UCP-1 protein content ( Figure 4B ). In line with this, we found a significantly elevated oxygen consumption rate in the cells upon 5 h of treatment with rimonabant (+23%, p<0.05; Figure 4C ). Furthermore, under these conditions oligomycin was less capable to suppress oxygen consumption rate (OCR) (Figure 4D ), pointing to enhanced uncoupling of oxidative phosphorylation. Enhanced uncoupling may be the result of enhanced intracellular lipolysis resulting in allosteric activation of UCP-1 (19) . Indeed, we found that rimonabant dose-dependently increased glycerol release ( Figure 4E ), pointing to increased intracellular lipolysis.
AMP-activated protein kinase (AMPK) serves as an intracellular energy sensor and activation of AMPK by means of phosphorylation results in enhanced fatty acid and glucose oxidation in a variety of tissues as well as controls lipolysis in white adipocytes (38) . Of note, CB1R blockade has been shown to increase AMPK phosphorylation in both liver cells (39) and white adipocytes (40) . In line with this, In contrast, rimonabant increased the phosphorylation of the PKA target residue on HSL (Ser563) ( Figure 4I) . As the Ser563 residue is phosphorylated by protein kinase A (PKA), which is itself activated by cAMP, this suggests that the cAMP/ PKA pathway at least in part mediates the enhanced intracellular lipolysis in brown adipocytes upon CB1R blockade. Indeed, as shown in Figure 4I , the combination of noradrenalin (which also signals through the cAMP/PKA pathway in brown adipocytes) and rimonabant even further enhanced p-HSL 563 content (+200%, p<0.01).
Moreover, in the presence of the PKA inhibitor H89 the enhanced pHSL 563 content induced upon rimonabant was blunted ( Figure 4J ).
Altogether, these data indicate that direct blockade of the CB1R on brown adipocytes directly stimulates intracellular lipolysis, UCP-1 protein content as well as uncoupling, which may at least in part be mediated by cAMP-PKA signaling. 
Strictly peripheral CB1R blockade by AM6545 reduces obesity and dyslipidemia and increases energy expenditure in DIO mice
To investigate whether peripheral CB1R blockade is sufficient to induce weight loss and reverse dyslipidemia in vivo, we treated DIO mice for four weeks with vehicle or AM6545, a peripherally restricted CB1R antagonist that has been previously shown not to elicit central side effects (17) . AM6545 markedly reduced body weight (-19%, p<0.001; Figure 5A ) and fat mass (-23%, p<0.01; Figure 5B ), without altering lean mass. AM6545 did not induce the initial transient decrease in food intake as seen with rimonabant, although a slight decrease was evident later during the treatment period ( Figure 5C ). However, total caloric intake was not affected. Furthermore, AM6545 substantially decreased plasma TG levels (-49%, p<0.05; Figure 5D ), which mostly resulted from a reduction in VLDL-TG (AUC -73%; Figure 5E ). In addition, AM6545 increased total energy expenditure ( Figure 5F ), which was due to an increase in both fat and carbohydrate oxidation (Figure 5G,H) . Thus, these data demonstrate that peripheral CB1R blockade is sufficient to diminish obesity and dyslipidemia in DIO.
Strictly peripheral CB1R blockade by AM6545 attenuates dyslipidemia by activating brown adipose tissue
To investigate whether peripheral CB1R blockade also diminished dyslipidemia by increasing FA uptake by BAT, we again assessed VLDL-TG production and clearance.
Just like rimonabant, AM6545 did not affect the production rates of VLDL-TG and VLDL-apoB (Figure 6A,B) or hepatic expression of lipogenic genes ( Figure 6C) .
Instead, AM6545 also accelerated clearance of [
3 H]TO-labeled VLDL-like emulsion particles from plasma ( Figure 6D ), accompanied by a marked increase of 3 H retention by BAT (+235%, p<0.01; Figure 6E) , and a decrease in 3 H uptake by sWAT (-51%, p<0.01).
In BAT, AM6545 increased expression of Lpl (+67%, p<0.05), Cd36 (+59%, p<0.05) and Ucp1 (+32%, p<0.05; Figure 6F ) and decreased lipid content (Figure 6G ), all pointing to increased BAT activity. AM6545 also decreased white adipocyte size (Supplemental Figure 4A ) and liver weight (-24%, p<0.001; Supplemental Figure 4B ) accompanied by a reduction in liver TG content (-17%, p<0.05) (Supplemental Figure 4C ) and lipid vacuole size (Supplemental Figure 4D) . Thus, peripheral CB1R blockade is sufficient to diminish dyslipidemia, and probably also obesity, by promoting VLDL-TG uptake and subsequent combustion of engulfed FA by BAT. 
DISCUSSION
Systemic CB1R blockade by the inverse CB1R agonist rimonabant alleviates the excess body weight and dyslipidemia that are associated with obesity, both in mice and in humans (8, 9, (11) (12) (13) . In this study, we demonstrate that systemic CB1R
blockade reverses DIO and reduces plasma VLDL-TG by selectively increasing VLDL-TG clearance by metabolically active BAT followed by combustion. Of note, the mechanism involves peripheral activation of BAT since the effects were still present at thermoneutrality and could be recapitulated by using the strictly peripheral (17) CB1R antagonist AM6545. Accordingly, cultured brown adipocytes could be activated by blockade of the CB1R with rimonabant.
Systemic CB1R blockade by rimonabant resulted in massive activation of BAT, as evidenced by reduced lipid content and increased UCP-1 expression, accompanied by increased energy expenditure, which is in accordance with previous studies (35, 41) . Of note, by performing kinetic studies with radioactively labeled VLDL-TG we provided clear evidence that the TG-lowering effect of rimonabant is due to increased uptake of TG-derived FAs by BAT. Since metabolically active BAT has been shown to be present and active in human adults (20) (21) (22) (23) , it is tempting to speculate that the body weight-reducing and TG-lowering effects of rimonabant previously found in obese subjects might be due to activation of BAT, although the precise role of BAT in TG metabolism in humans remains to be established.
Previous studies suggested central CB1R blockade as the main mechanism by which rimonabant induces BAT activation, resulting in increased sympathetic outflow towards BAT and increased energy expenditure (35, 41) . For instance, Bajzer and colleagues (36) reported that denervation of BAT in mice blunted the effect of rimonabant on insulin-mediated glucose uptake. However, in their study, the increase in energy expenditure and the reduction in body weight and fat mass were not blunted by BAT denervation, suggesting that a peripheral mechanism is at least in part involved in these beneficial effects. Indeed, we found that treatment of DIO mice with the strictly peripheral CB1R antagonist AM6545 still resulted in increased energy expenditure accompanied by increased uptake of TG-derived FAs by BAT as well as significant weight loss and reduction in dyslipidemia. Furthermore, we
showed that the CB1R is highly expressed in BAT. It is important to realize that this does not exclude the possibility that presynaptic CB1R on peripheral sympathetic nerve terminals innervating BAT may be the peripheral target whose blockade enhances BAT activation through enhanced noradrenalin release. However, the fact that we found that noradrenalin content in BAT was only increased upon treatment with rimonabant at 21°C and not at thermoneutrality or upon AM6545 treatment (data not shown), makes this mechanism less likely. In line with this, we found that rimonabant directly activated brown adipocytes in vitro, further supporting the possibility of a peripheral mode of action of CB1R blockade in BAT.
We found that systemic blockade of the CB1R by rimonabant did not affect VLDL-TG production following either systemic or selective peripheral CB1R blockade. In contrast, a study by Tam and colleagues (17) reported that blocking the peripheral CB1R by AM6545 treatment resulted in a marked increase in the production of VLDL-TG in both DIO C57Bl/6 and leptin-deficient ob/ob mice. This might be explained by differences in study set-up, since Tam and colleagues measured VLDL-TG production after 1 week of treatment while in the present study VLDL-TG production was measured after 4 weeks. Likely, CB1R blockade transiently increases VLDL-TG production, leading to a fast initial reduction in hepatic steatosis as was also observed in their study. The subsequent normalization in VLDL production that we found in our study after 4 weeks of treatment may then be the consequence of a lower supply of FFAs towards the liver for incorporation into VLDL-TG, since these are efficiently cleared by BAT.
While we provide clear evidence that the TG-lowering effect of CB1R blockade is due to peripheral activation of BAT, the mechanism by which CB1R blockade lowers body weight and fat mass is less clear and no consistent mechanism has been reported up to date. Although BAT activation has been repeatedly shown to decrease body weight and fat mass (18, 42, 43) , we cannot exclude that CB1R blockade on peripheral tissues other than BAT may contribute to the weight-reducing effect.
For instance, the CB1R has been shown to be present on white adipocytes (16) and treatment of mice with rimonabant and AM6545 increased lipolysis (17, 44, 45) .
Accordingly, we also found that rimonabant increased mRNA expression of Hsl in subcutaneous WAT. The question remains whether the effect of rimonabant on WAT lipolysis is a primary effect or occurs as a consequence of enhanced BAT activation.
As we did not observe a direct effect of rimonabant on glycerol release in 3T3L1 white adipocytes it is more likely that the enhanced WAT lipolysis occurs secondary to BAT activation. Furthermore, the weight-reducing effect of global CB1R blockade is also at least in part due to an initial transient decrease in food intake induced by rimonabant. The greater efficacy of rimonabant over AM6545 in reducing body weight is then likely explained by the fact that AM6545 did not affect total caloric intake over the treatment period, as has been shown before (17) . Thus, future studies are needed to elucidate the specific contribution of BAT in the weight-reducing effect of (peripheral) CB1R blockade.
It is interesting to speculate on the possible intracellular mechanisms by which CB1R blockade enhances BAT activity. One of the hallmarks of brown adipocyte activation is enhanced intracellular lipolysis, resulting in release of FA that can subsequently allosterically activate UCP-1 (19) . In search for the pathway that is connected to induction of intracellular lipolysis by CB1R blockade, we measured the phosphorylation state of HSL on various regulatory residues in T37i cells upon treatment with rimonabant. We found that rimonabant selectively enhanced p-HSL 563 , the residue that is phosphorylated by PKA, and that this effect could be blocked by addition of the PKA inhibitor H89. As PKA is itself activated by enhanced intracellular cAMP levels, this suggests that rimonabant enhances the cAMP/ PKA pathway in brown adipocytes. This mechanism is not surprising as the major mediators in CB1R signaling are in fact G-proteins of the G(i/o) family that inhibit adenylyl cyclases (46) . Moreover, CB1R agonism in a variety of cell types inhibits adenylyl cyclase activity and thus cAMP levels (46) . In addition, we found that CB1R
blockade resulted in increased AMPK phosphorylation in brown adipocytes, which is in accordance with previous studies performed in hepatocytes (39) and white adipocytes (40) . However, as AMPK may be activated in case of low intracellular ATP levels, the effect of rimonabant on the kinase might be secondary to enhanced uncoupling of oxidative phosphorylation induced by rimonabant. Indeed, we found that p-AMPK was only enhanced in brown adipocytes after chronic and not acute stimulation with rimonabant. Thus, we propose a mechanism ( 
